Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad R Ritch

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Prostate Cancer and Prostatic Diseases|September 27, 2024
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS scoreHelen Y Hougen, Isildinha M Reis, Sunwoo Han, et al.
The Journal of Urology|December 28, 2020
Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted BiopsySanoj Punnen, Radka Stoyanova, Deukwoo Kwon, et al.
Academic Radiology|December 18, 2024
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of ProgressionIsabella M Kimbel, Veronica Wallaengen, Evangelia I Zacharaki, et al.
BJU International|May 6, 2026
Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trialSeyed Hossein Hosseini Sharifi, Adam Williams, Jonathan T Ryan, et al.
Cancers|March 14, 2026
mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active SurveillanceVeronica Wallaengen, Evangelia I Zacharaki, Mohammad Alhusseini, et al.
BJU International|February 27, 2026
Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)Ankur Malpani, Jonathan T Ryan, Hui Yu, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 20, 2026
MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning modelNoah C Lowry, Adrian L Breto, Veronica Wallaengen, et al.
European Urology Focus|December 12, 2024
Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST TrialTarek Ajami, Hui Yu, Joao G Porto, et al.
The Journal of Urology|June 20, 2025
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance TrialPedro F S Freitas, Archan Khandekar, Joao G Porto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder CancerJohn L Gore, Erika M Wolff, Michael G Nash, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Prostate Cancer and Prostatic Diseases|September 27, 2024
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS scoreHelen Y Hougen, Isildinha M Reis, Sunwoo Han, et al.
The Journal of Urology|December 28, 2020
Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted BiopsySanoj Punnen, Radka Stoyanova, Deukwoo Kwon, et al.
Academic Radiology|December 18, 2024
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of ProgressionIsabella M Kimbel, Veronica Wallaengen, Evangelia I Zacharaki, et al.
BJU International|May 6, 2026
Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trialSeyed Hossein Hosseini Sharifi, Adam Williams, Jonathan T Ryan, et al.
Cancers|March 14, 2026
mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active SurveillanceVeronica Wallaengen, Evangelia I Zacharaki, Mohammad Alhusseini, et al.
BJU International|February 27, 2026
Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)Ankur Malpani, Jonathan T Ryan, Hui Yu, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 20, 2026
MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning modelNoah C Lowry, Adrian L Breto, Veronica Wallaengen, et al.
European Urology Focus|December 12, 2024
Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST TrialTarek Ajami, Hui Yu, Joao G Porto, et al.
The Journal of Urology|June 20, 2025
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance TrialPedro F S Freitas, Archan Khandekar, Joao G Porto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder CancerJohn L Gore, Erika M Wolff, Michael G Nash, et al.
Pageof 9